The United States has agreed to provide an experimental Ebola treatment to the Democratic Republic of Congo for use in a clinical trial targeting the country's latest outbreak. The drug, known as MBP134 and developed by California-based Mapp Biopharmaceutical , had initially been reserved for American patients. However, its deployment in DR Congo is expected to support ongoing research and could accelerate regulatory approval in the United States. Meanwhile, the World Health Organization says clinical trials of Remdesivir —an antiviral drug previously used to treat COVID-19 —will begin next week among Ebola patients. Efforts to contain the outbreak have been complicated by the Bundibugyo strain of the Ebola virus , for which there is currently no approved treatment or vaccine. Scientists are working to develop four potential vaccines , with two candidates expected to enter clinical trials within the next two months. However, progress in developing new treatments and vaccines h...
Privacy Policy Last Updated: August 26, 2026 Welcome to Powel’s Journal . Your privacy is important to us. This Privacy Policy explains how we collect, use, and protect information when you visit or interact with our website. 1. Information We Collect Powel’s Journal may collect limited information automatically when you visit our website. This may include your IP address, browser type, device information, pages visited, time spent on the website, and other technical information. If you voluntarily contact us, leave a comment, or submit information through our website, we may receive information that you choose to provide, such as your name and email address. 2. How We Use Information Information collected may be used to: Operate and maintain our website. Improve our content and user experience. Understand how visitors use our website. Respond to enquiries, comments, and messages. Monitor website performance and security. Display relevant advertisements. We do not sell ...